A novel biofilm-Plus whole cell quartz crystal microbalance (QCM) biosensor developed for use in cancer diagnosis, pathogen detection, drug discovery, cancer prognosis and clinical treatment management

The Portal is a joint project of MATTO and the MTTC. The development and implementation of the portal has been paid for by the MTTC, Beth Israel Deaconess Medical Center, Boston Biomedical Research Institute, Boston University, Brandeis University, Caritas St. Elizabeth's Medical Center, Boston Children's Hospital, Dana Farber Cancer Institute, Harvard University, Joslin Diabetes Center, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, McLean Hospital, Northeastern University, The Schepens Eye Research Institute, and Tufts University.

Intellectual Property

ID:		UML 02-24
IP Type:		Licensable Technology
Title:		A novel biofilm-Plus whole cell quartz crystal microbalance (QCM) biosensor developed for use in cancer diagnosis, pathogen detection, drug discovery, cancer prognosis and clinical treatment management
Inventor:		Kenneth A. Marx
Summary:		The quartz crystal microbalance (QCM) is a device capable of assaying and characterizing nanogram masses. Using this device, materials and a protocol have been developed to assay living biopsy cells that result in the diagnosis of malignancy, as well as quantifying the efficacy of various chemotherapies against malignant biopsy cells. The QCM has excellent repeatability for characterization of cells, using changes in the crystal oscillation frequency and changes in motional resistance. This patent pending invention has shown to be useful for diagnosis of biopsies, using as little as 2% of a typical needle biopsy. The measurement will provide clear indication of the type of malignancy or determine if the sample is benign. The complete turnaround time is a maximum of 24 hours, and strong indications are indicated as quickly as 6 hours. The invention may be used to test the efficacy of therapies on cancerous cells, with the potential for nearly immediate feedback to provide optimum therapy on an individual basis. This would be extremely valuable in shortening treatment time and beneficial for drug evaluation and discovery.
Tech Type:		Nanotechnology/NEMS
URL:		http://www.uml.edu/cvip
Contact:		Susu Wong, 978 934 4722, susu_wong@uml.edu
Organization:		University of Massachusetts Lowell

Display all intellectual properties for Kenneth A. Marx
Display all intellectual properties for University of Massachusetts Lowell